Pregnancy of Laximed in details
Systemic exposure following maternal use of Laximed is limited. Plasma concentrations of BHPM (the active metabolite of Laximed) are low (median: 61 ng/mL; range: 20 to 118 ng/mL) and the pharmacokinetics are highly variable following oral doses of 10 mg/day for 7 days to women immediately postpartum (Friedrich 2011).
Treatment of constipation in pregnant women is similar to that of nonpregnant patients and medications may be used when diet and lifestyle modifications are not effective. Agents other than Laximed are preferred as initial treatment. Stimulant laxatives, including Laximed, are not recommended for chronic use, but may be used intermittently when needed (ACG [Christie 2007]).
Laximed breastfeeding
There are no data on the excretion of Laximed into human milk.
See references
References for pregnancy information
- "Product Information. Dulcolax (Laximed)." Ciba Self-Medication Inc, Woodbridge, NJ.
References for breastfeeding information
- "Product Information. Dulcolax (Laximed)." Ciba Self-Medication Inc, Woodbridge, NJ.
References
- DailyMed. "BISACODYL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubMed Health. "Dulcolax: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
- FDA Pharm Classes. "FDA Pharmacological Classification: FDA published a final rule that amended the requirements for the content and format of approved labeling (prescribing information) for human prescription drug and biological products in January 2006.". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
